The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 40-44

  van Riel, Piet L C M ^a,b   Renskers, Lisanne ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Bernhoven ^*  (Netherlands)

Author keywords

DAS; DAS28; Personalised medicine; Rheumatoid arthritis; Self monitoring

Indexed keywords

ARTICLE; CLINICAL PRACTICE; DAS28; DISEASE ACTIVITY SCORE; DISEASE COURSE; HUMAN; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; DISABILITY; ELECTRONIC HEALTH RECORD; HEALTH STATUS; HEALTH STATUS INDICATOR; JOINT; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PSYCHOLOGY; QUESTIONNAIRE; REPRODUCIBILITY; RHEUMATOLOGY; SELF CARE; SEVERITY OF ILLNESS INDEX; TELEMEDICINE; TIME FACTOR;

ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DISEASE PROGRESSION; ELECTRONIC HEALTH RECORDS; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; JOINTS; PATIENT REPORTED OUTCOME MEASURES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; RHEUMATOLOGY; SELF CARE; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TELEMEDICINE; TIME FACTORS;

EID: 85015847910     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. van RIEL PLCM, van de PUTTE LBA: Clinical assessment and clinical trials in rheumatoid arthritis. Curr Opin Rheumatol 1994; 6: 132-9.
2. Van de HEIJDE DMFM, van't HOF MA, van RIEL PLCM, van de PUTTE LBA: Validity of single variables and indices to measure disease activity in Rheumatoid Arthritis. J Rheumatol 1993; 20: 538-41.
3. Van de HEIJDE DMFM, van't HOF MA, van RIEL PLCM et al.: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
4. FUCHS HA, BROOKS RH, CALLAHAN LF, PINCUS T: A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 1989; 32: 531-7.
5. PREVOO MLL, van't HOF MA, KUPER HH, van LEEUWEN MA, van de PUTTE LBA, van RIEL PLCM: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with Rheumatoid Arthritis. Arthritis Rheum 1995; 38: 44-48.
6. Van der HEIJDE DMFM, van't HOF MA, van RIEL PLCM, van LEEUWEN MA, van RIJSWIJK MH, van de PUTTE LBA: Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992; 51: 177-81.
7. Van der HEIJDE DMFM, van RIEL PLCM, van LEEUWEN MA, van't HOF MA, van RIJSWIJK MH, van de PUTTE LBA: Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992; 31: 519-25.
8. WELSING PMJ, van GESTEL AM, SWINKELS HL, KIEMENEY LALM, van RIEL PLCM: The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009-17.
9. WELSING PMJ, LANDEWé RB, van RIEL PLCM et al.: The relationship between disease activity and radiological progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004; 50: 2082-93.
10. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35
11. Van GESTEL AM, HAAGSMA CJ, van RIEL PLCM: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50
12. Van GESTEL AM, ANDERSON JJ, van RIEL PLCM et al.: ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999; 26: 705-11.
13. HUBER M, KNOTTNERUS JA, GREEN L et al.: How should we define health? BMJ 2011; 343: d4163.
14. FELSON DT, SMOLEN JS, WELLS G et al.: American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573-86.
15. PUNDER YMR, FRANSEN J, KIEVIT W et al.: The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 2012; 51: 1610-7.
16. PREVOO MLL, van GESTEL AM, van't HOF MA, van RIJSWIJK MH, van de PUTTE LBA, van RIEL PLCM: Remission in a prospective study of patients with rheumatoid arthritis. Br J Rheumatol 1996; 35: 1101-5.
17. FRANSEN J, WELSING PMJ, van RIEL PLCM: Remission in RA: Agreement of the Disease Activity Score (DAS28) with the ARA preliminary remission criteria. Ann Rheum Dis 2003; 62 (Suppl. 1): 68.
18. Van RIEL PLCM, van GESTEL AM: Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 2000; 59 (Suppl. I): i28-i31.
19. De PUNDER YMR, JANSEN TLThA, van EDE AE, den BROEDER AA, van RIEL PLCM, FRANSEN J: Personalizing treatment targets in rheumatoid arthritis by using a simple prediction model. J Rheumatol 2015; 42: 398-404.
20. TYMMS K, ZOCHLING J, SCOTT J et al.: Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity. Arthritis Care Res 2014; 66: 190-6.
21. MORELAND LW, RUSSELL AS, PAULUS HE: Management of rheumatoid arthritis: the historical context. J Rheumatol 2001; 28: 1431-52.
22. Van RIEL PLCM, SCHUMACHER HR: How does one assess early rheumatoid arthritis in daily clinical practice? Best Pract Res Clin Rheumatol 2001; 15: 67-76.
23. Van RIEL PLCM, Van GESTEL AM: Area under the curve for the American College of Rheumatology improvement criteria: a valid addition to existing criteria in rheumatoid arthritis? Arthritis Rheum 2001; 44: 1719-22.
24. FRANSEN J, STUCKI G, van RIEL PLCM: The merits of monitoring: should we follow all our rheumatoid arthritis patients in daily practice? Rheumatology 2002; 41: 601-4.
25. WOLFE F, CUSH JJ, O'DELL JR et al.: Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001; 28: 1413-30.
26. Transparency in Healthcare B.V. (TiH) (2016) Available from: http://www.tihealthcare. nl/en.
27. FRANSEN J, WELSING PMJ, De KEIJZER RMH, van RIEL PLCM: Development and validation of the DAS28 using CRP. Ann Rheum Dis 2003; 62 (Suppl. 1): 10.
28. Van LEEUWEN MA, van RIJSWIJK MH: Acute phase proteins in the monitoring of inflammatory disorders. Bailliere's Clin Rheumatol 1994; 8: 531-52.
29. Van RIEL PLCM, FRANSEN J, SCOTT DL: EULAR handbook of clinical assessments in rheumatoid arthritis. Alphen aan den Rijn: van Zuiden Communications 2004.
30. Medical and Educational Goods and Services (MEGS): iMonitor (2016). Available from: http://www.pfizer.co.uk/content/medical-and-educational-goods-and-servicesmegs-imonitor.
31. BERTHELOT J, BLANCHAIS A, MARHADOUR T, Le GOFF B, MAUGARS Y, SARAUX A: Fluctuations in disease activity scores for inflammatory joint disease in clinical practice: do we need a solution? Joint Bone Spine 2009; 76: 126-8.
32. BERTHELOT JM, TORTELLIER L, LAVYBREGEON D, Le GOFF B, MAUGARS Y: High intraindividual week-to-week variability in BASDAI and BASFI values: Are several evaluations needed before starting or stopping TNF-a antagonist therapy for spondyloarthropathies? Joint Bone Spine 2008; 75: 167-71.
33. El MIEDANY Y: PROMs in inflammatory arthritis: moving from static to dynamic. Clin Rheumatol 2013; 32: 735-42.
34. GOSSEC L, DOUGADOS M, DIXON W: Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open 2015; 1: p. e000019.